Published in N Engl J Med on April 10, 2014
Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. Gut (2014) 2.33
A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut (2014) 1.84
Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. Cancer Cell (2016) 1.14
Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals. BMC Med (2017) 0.96
Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol (2014) 0.96
RACK1 controls IRES-mediated translation of viruses. Cell (2014) 0.95
Hepatitis C virus-induced hepatocellular carcinoma. Clin Mol Hepatol (2015) 0.91
Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection. Viruses (2015) 0.91
Results from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation Program. J Gen Intern Med (2015) 0.90
New treatment strategies for hepatitis C infection. World J Hepatol (2015) 0.88
Future of therapy for Hepatitis C in India: A Matter of Accessibility and Affordability? J Clin Exp Hepatol (2014) 0.86
Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors. J Virol (2014) 0.84
Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepat Oncol (2015) 0.84
Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a "special population"? World J Hepatol (2015) 0.81
Treatment strategies for chronic hepatitis C prior to and following liver transplantation. World J Hepatol (2016) 0.80
New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A. J Virol (2015) 0.80
Epidemiology of medications use in pregnancy. Semin Perinatol (2015) 0.78
Hepatitis C Virus Treatment Revolution: Eastern European Story. Hepat Mon (2015) 0.77
Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies. Expert Rev Vaccines (2016) 0.77
Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection. PLoS Comput Biol (2015) 0.77
Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients. J Immunol Res (2016) 0.76
Identification of a Potent and Broad-Spectrum Hepatitis C Virus Fusion Inhibitory Peptide from the E2 Stem Domain. Sci Rep (2016) 0.76
Native folding of a recombinant gpE1/gpE2 heterodimer vaccine antigen from a precursor protein fused with Fc IgG. J Virol (2016) 0.76
Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus. J Virol (2016) 0.76
Supplementing Conventional Treatment with Pycnogenol® May Improve Hepatitis C Virus-Associated Type 2 Diabetes: A Mini Review. J Clin Transl Hepatol (2016) 0.75
Functional differences in hepatitis C virus nonstructural (NS) 3/4A- and 5A-specific T cell responses. Sci Rep (2016) 0.75
Conditional Inducible Triple-Transgenic Mouse Model for Rapid Real-Time Detection of HCV NS3/4A Protease Activity. PLoS One (2016) 0.75
One-Step Recovery of scFv Clones from High-Throughput Sequencing-Based Screening of Phage Display Libraries Challenged to Cells Expressing Native Claudin-1. Biomed Res Int (2015) 0.75
Insights for hepatitis C virus related hepatocellular carcinoma genetic biomarkers: Early diagnosis and therapeutic intervention. World J Hepatol (2016) 0.75
Future therapy of portal hypertension in liver cirrhosis - a guess. F1000Prime Rep (2014) 0.75
Clinical development of hepatitis C virus host-targeting agents. Lancet (2017) 0.75
Personalized management of hepatocellular carcinoma based on molecular information: future prospects. Clin Liver Dis (Hoboken) (2015) 0.75
Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure. Viruses (2016) 0.75
A new HCV mouse model on the block. Cell Res (2014) 0.75
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. PLoS One (2017) 0.75
Viral hepatitis: A new HCV cell culture model for the next clinical challenges. Nat Rev Gastroenterol Hepatol (2015) 0.75
Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma. Curr Opin Virol (2016) 0.75
A cinnamon-derived procyanidin type A compound inhibits hepatitis C virus cell entry. Hepatol Int (2017) 0.75
Postexposure prophylaxis after hepatitis C occupational exposure in the interferon-free era. Curr Opin Infect Dis (2016) 0.75
miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis. Gut (2017) 0.75
Evidence for association between hepatitis C virus and Parkinson's disease. Neurol Sci (2017) 0.75
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A (2007) 3.13
Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J Exp Med (2010) 3.09
Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. Proc Natl Acad Sci U S A (2013) 2.99
Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem (2003) 2.94
Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology (2011) 2.51
Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha. Hepatology (2013) 2.28
Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology (2007) 2.25
Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med (2012) 2.14
Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology (2006) 1.96
Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology (2010) 1.87
A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology (2011) 1.85
Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines. J Virol (2002) 1.84
APOBEC-mediated interference with hepadnavirus production. Hepatology (2005) 1.82
Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol (2006) 1.71
Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol (2010) 1.67
Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles. Hepatology (2010) 1.65
Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol (2010) 1.63
IFN-λ receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-λ3 genotype and with nonresponsiveness to IFN-α therapies. J Exp Med (2014) 1.61
CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection. J Virol (2007) 1.61
Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology (2010) 1.58
Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. PLoS Pathog (2010) 1.45
Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J Hepatol (2010) 1.42
Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms. J Virol (2010) 1.39
HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe (2013) 1.37
Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol (2010) 1.37
Hepatitis C virus infection sensitizes human hepatocytes to TRAIL-induced apoptosis in a caspase 9-dependent manner. J Immunol (2008) 1.36
Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology (2015) 1.36
Hepatitis C virus infection of neuroepithelioma cell lines. Gastroenterology (2010) 1.35
Hepatitis C virus entry: molecular biology and clinical implications. Hepatology (2006) 1.34
Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. J Virol (2004) 1.29
Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges. J Hepatol (2012) 1.22
Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci U S A (2007) 1.22
Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies. J Virol (2010) 1.19
Reconstitution of the entire hepatitis C virus life cycle in nonhepatic cells. J Virol (2012) 1.18
Hepatitis C virus entry. Curr Top Microbiol Immunol (2013) 1.17
Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis. J Gen Virol (2006) 1.17
Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines (2009) 1.16
Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection. PLoS One (2007) 1.16
Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Gastroenterology (2008) 1.16
Hepatitis C virus induces CD81 and claudin-1 endocytosis. J Virol (2012) 1.14
Scavenger receptor class B type I and hepatitis C virus infection of primary tupaia hepatocytes. J Virol (2005) 1.14
Interferon-γ-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C. Gastroenterology (2012) 1.12
Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease. Viruses (2013) 1.12
Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. Blood (2005) 1.11
Primary hepatocytes of Tupaia belangeri as a potential model for hepatitis C virus infection. J Clin Invest (2002) 1.11
Sustained delivery of siRNAs targeting viral infection by cell-degradable multilayered polyelectrolyte films. Proc Natl Acad Sci U S A (2008) 1.09
Scavenger receptor class B is required for hepatitis C virus uptake and cross-presentation by human dendritic cells. J Virol (2008) 1.09
Host neutralizing responses and pathogenesis of hepatitis C virus infection. Hepatology (2008) 1.08
Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. Trends Mol Med (2010) 1.07
The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. Hepatology (2012) 1.07
Matrigel-embedded 3D culture of Huh-7 cells as a hepatocyte-like polarized system to study hepatitis C virus cycle. Virology (2012) 1.06
Mouse models for the study of HCV infection and virus-host interactions. J Hepatol (2008) 1.05
Hepatitis C virus is a weak inducer of interferon alpha in plasmacytoid dendritic cells in comparison with influenza and human herpesvirus type-1. PLoS One (2009) 1.05
A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses. J Infect Dis (2012) 1.05
A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission. PLoS One (2013) 1.04
Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps. J Biol Chem (2012) 1.03
Inhibitory effect of adefovir and lamivudine on the initiation of hepatitis B virus infection in primary tupaia hepatocytes. Hepatology (2003) 1.00
Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry. Hepatology (2014) 0.99
Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. J Hepatol (2012) 0.99
Hepatitis C virus infection and related liver disease: the quest for the best animal model. Front Microbiol (2013) 0.99
Hepatitis C virus vaccines--progress and perspectives. Microb Pathog (2013) 0.98
Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees. Hepatology (2011) 0.97
Novel interactions of glycosaminoglycans and bacterial glycolipids mediate binding of enterococci to human cells. J Biol Chem (2009) 0.97
A look behind closed doors: interaction of persistent viruses with dendritic cells. Nat Rev Microbiol (2010) 0.96
TIP47 plays a crucial role in the life cycle of hepatitis C virus. J Hepatol (2013) 0.95
GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection. Curr Opin Mol Ther (2009) 0.93
Three different functional microdomains in the hepatitis C virus hypervariable region 1 (HVR1) mediate entry and immune evasion. J Biol Chem (2012) 0.91
HCV glycoprotein E2 is a novel BDCA-2 ligand and acts as an inhibitor of IFN production by plasmacytoid dendritic cells. Blood (2012) 0.91
A first step towards a mouse model for hepatitis C virus infection containing a human immune system. J Hepatol (2011) 0.90
Hepatitis C virus fails to activate NF-κB signaling in plasmacytoid dendritic cells. J Virol (2011) 0.89
RNAi: a powerful tool to unravel hepatitis C virus-host interactions within the infectious life cycle. J Hepatol (2007) 0.89
Production of infectious hepatitis C virus in tissue culture: a breakthrough for basic and applied research. J Hepatol (2005) 0.89
Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes by using monoclonal antibodies. J Virol (2013) 0.89
Host cell responses induced by hepatitis C virus binding. Hepatology (2006) 0.89
Frequent compartmentalization of hepatitis C virus with leukocyte-related amino acids in the setting of liver transplantation. J Infect Dis (2008) 0.88
Acute Mycoplasma pneumoniae infection presenting as cholestatic hepatitis. J Clin Microbiol (2003) 0.87
Additional glycosylation within a specific hypervariable region of subtype 3a of hepatitis C virus protects against virus neutralization. J Infect Dis (2013) 0.87
Low perforin expression of early differentiated HCV-specific CD8+ T cells limits their hepatotoxic potential. J Hepatol (2012) 0.86
EWI-2wint promotes CD81 clustering that abrogates Hepatitis C Virus entry. Cell Microbiol (2013) 0.86
The major form of hepatitis C virus alternate reading frame protein is suppressed by core protein expression. Nucleic Acids Res (2008) 0.86
Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy. Front Biosci (Landmark Ed) (2009) 0.86
Hepatitis C virus envelope glycoprotein signatures are associated with treatment failure and modulation of viral entry and neutralization. J Infect Dis (2013) 0.85
Interaction of hepatitis C virus envelope glycoprotein E2 with the large extracellular loop of tupaia CD81. World J Gastroenterol (2009) 0.83
miR-122 acts as a tumor suppressor in hepatocarcinogenesis in vivo. J Hepatol (2012) 0.82
Distinct intracellular trafficking of hepatitis C virus in myeloid and plasmacytoid dendritic cells. J Virol (2010) 0.81
Toll-like receptor 2 senses hepatitis C virus core protein but not infectious viral particles. J Innate Immun (2009) 0.80
Challenges for HCV vaccine development in HIV-HCV coinfection. Expert Rev Vaccines (2012) 0.80
Templated assembly of albumin-based nanoparticles for simultaneous gene silencing and magnetic resonance imaging. Nanoscale (2014) 0.79
Interferon-lambda polymorphisms and hepatitis C virus clearance revisited. Hepatology (2013) 0.79
A novel target of hepatitis B virus mutations: splicing of surface RNA. Hepatology (2005) 0.78
Rapid synchronization of hepatitis C virus infection by magnetic adsorption. J Virol Methods (2009) 0.78
Neutralizing antibodies and pathogenesis of hepatitis C virus infection. Viruses (2012) 0.78
Genotype 1 hepatitis C virus envelope features that determine antiviral response assessed through optimal covariance networks. PLoS One (2013) 0.78
Closing the gap: the tight junction protein occludin and hepatitis C virus entry. Hepatology (2009) 0.78
Acute infection with a single hepatitis C virus strain in dialysis patients: Analysis of adaptive immune response and viral variability. J Hepatol (2009) 0.77
Functional and Biochemical Characterization of Hepatitis C Virus (HCV) Particles Produced in a Humanized Liver Mouse Model. J Biol Chem (2015) 0.77
HCV entry and neutralizing antibodies: lessons from viral variants. Future Microbiol (2009) 0.77
Severe cerebral vasculitis as primary manifestation of hepatitis B-associated polyarteritis nodosa. J Hepatol (2002) 0.77
EWI-2wint--a host cell factor inhibiting hepatitis C virus entry. J Hepatol (2008) 0.77